Hales Dana, Tefas Lucia Ruxandra, Tomuță Ioan, Moldovan Cristian, Gulei Diana, Munteanu Raluca, Porfire Alina
Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, University of Medicine and Pharmacy "Iuliu Haţieganu", 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Research Center for Advanced Medicine-MedFUTURE, University of Medicine and Pharmacy "Iuliu Haţieganu", 4-6 L. Pasteur Street, 400349 Cluj-Napoca, Romania.
Pharmaceutics. 2020 Oct 27;12(11):1027. doi: 10.3390/pharmaceutics12111027.
The purpose of this study was to apply the quality-by-design (QbD) approach for the development of colon-targeted curcumin-loaded polymeric microparticles (Col-CUR-MPs). The proportion of the enterosoluble polymer (Eudragit FS) in the polymeric matrix, curcumin concentration, and the concentration of the polymer mixture (Eudragit FS-polycaprolactone) were identified as potential risk factors for the quality of the final product following risk assessment. The influence of these variables on the critical quality attributes (CQAs) of Col-CUR-MPs was investigated. Therefore, a central composite face experimental design was used in order to determine the functional relationships between variables and product CQAs. The obtained regression model and contour plots were used to establish the design space. Finally, the model was validated by preparing two microparticulate formulations, one corresponding to the robust setpoint from within the design space and one outside the established design space, and calculating the percentage bias between the experimental and predicted values. The in vivo study, which was conducted on a fluorescein-loaded formulation that corresponded to the robust setpoint determined by QbD and that contained a mixture of polycaprolactone and Eudragit FS (60:40, ), confirmed the colon-targeting qualities of this formulation.
本研究的目的是应用质量源于设计(QbD)方法来开发结肠靶向载姜黄素聚合物微粒(Col-CUR-MPs)。在风险评估后,确定了聚合物基质中肠溶聚合物(尤特奇FS)的比例、姜黄素浓度以及聚合物混合物(尤特奇FS-聚己内酯)的浓度为最终产品质量的潜在风险因素。研究了这些变量对Col-CUR-MPs关键质量属性(CQAs)的影响。因此,采用中心复合表面实验设计来确定变量与产品CQAs之间的函数关系。利用所得的回归模型和等高线图建立设计空间。最后,通过制备两种微粒制剂对模型进行验证,一种对应于设计空间内的稳健设定点,另一种在既定设计空间之外,并计算实验值与预测值之间的偏差百分比。在对一种载有荧光素的制剂进行的体内研究中,该制剂对应于由QbD确定的稳健设定点,并且含有聚己内酯和尤特奇FS的混合物(60:40),证实了该制剂的结肠靶向特性。